{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Song EJ"],"funding":["Ministry of Science and ICT"],"pagination":["31-51"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7028899"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["11(1)"],"pubmed_abstract":["<h4>Background</h4>Prevention and improvement of disease symptoms are important issues, and probiotics are suggested as a good treatment for controlling the obesity. Human gut microbiota has different community structures. Because gut microbial composition is assumed to be linked to probiotic function, this study evaluated the efficacy of probiotics on obesity-related clinical markers according to gut microbial enterotype.<h4>Methods</h4>Fifty subjects with body mass index over 25 kg/m<sup>2</sup> were randomly assigned to either the probiotic or placebo group. Each group received either unlabeled placebo or probiotic capsules for 12 weeks. Body weight, waist circumference, and body composition were measured every 3 weeks. Using computed tomography, total abdominal fat area and visceral fa"],"journal":["The EPMA journal"],"pubmed_title":["Effect of probiotics on obesity-related markers per enterotype: a double-blind, placebo-controlled, randomized clinical trial."],"pmcid":["PMC7028899"],"funding_grant_id":["E0170601-03"],"pubmed_authors":["Lim S","Nam MH","Nam YD","Han K","Kim H","Song EJ","Lim TJ","Chung MJ"],"additional_accession":[]},"is_claimable":false,"name":"Effect of probiotics on obesity-related markers per enterotype: a double-blind, placebo-controlled, randomized clinical trial.","description":"<h4>Background</h4>Prevention and improvement of disease symptoms are important issues, and probiotics are suggested as a good treatment for controlling the obesity. Human gut microbiota has different community structures. Because gut microbial composition is assumed to be linked to probiotic function, this study evaluated the efficacy of probiotics on obesity-related clinical markers according to gut microbial enterotype.<h4>Methods</h4>Fifty subjects with body mass index over 25 kg/m<sup>2</sup> were randomly assigned to either the probiotic or placebo group. Each group received either unlabeled placebo or probiotic capsules for 12 weeks. Body weight, waist circumference, and body composition were measured every 3 weeks. Using computed tomography, total abdominal fat area and visceral fa","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Mar","modification":"2025-04-05T14:55:14.419Z","creation":"2025-02-19T01:56:01.317Z"},"accession":"S-EPMC7028899","cross_references":{"pubmed":["32140184"],"doi":["10.1007/s13167-020-00198-y"]}}